Guidelines: Finnish Medical Association Duodecim Guidelines (Finland): Difference between revisions
From Beacon
(Created page with "{{#subobject:Finnish Medical Association Duodecim Guidelines |dct:title=Finnish Medical Association Duodecim Guidelines |datatype=guideline }} '''Sponsor, manager or home institution:''' Duodecim of the Finnish Medical Society and other institutions. '''Primary purpose:''' To provide independent national treatment recommendations based on research evidence. '''Type of information:''' Treatment recommendations; Epidemiology and etiology; Prevalence classification and...") |
No edit summary |
||
| Line 1: | Line 1: | ||
{{ | {{forproviders}} | ||
Go back to [[Finland]] page | |||
}} | |||
'''Sponsor, manager or home institution:''' Duodecim of the Finnish Medical Society and other institutions. | '''Sponsor, manager or home institution:''' Duodecim of the Finnish Medical Society and other institutions. | ||
Revision as of 19:51, 1 December 2023
Go back to Finland page
Sponsor, manager or home institution: Duodecim of the Finnish Medical Society and other institutions.
Primary purpose: To provide independent national treatment recommendations based on research evidence.
Type of information: Treatment recommendations; Epidemiology and etiology; Prevalence classification and histological classification; Diagnostics; Monitoring; Quality of life of patients of prostate, lung, oral cancer and palliative care and hospice care recommendations.
Access to information: List of guidelines [1].
